# AbbVie Acquires Apogee Therapeutics for Nearly $11 Billion in Top Immunology Deal of 2026

> ma · REPORTED · 2026-06-01

AbbVie acquired immunology-focused Apogee Therapeutics for nearly $11 billion, one of the largest M&A deals in the healthcare sector year-to-date in 2026, as the company moved to reinforce its immunology pipeline ahead of the looming Dupixent patent cliff. The deal reflects intensifying large-cap pharma portfolio-replenishment activity in high-growth therapeutic areas.

- Company: AbbVie / Apogee Therapeutics
- Sector: therapeutics
- Primary source: https://www.biospace.com/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.